HuMax-TF-ADC and Daratumumab Data to Be Presented at 2015

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
HuMax-TF-ADC and Daratumumab Data to Be Presented at 2015 ASCO Annual Meeting

Company Announcement

  • First clinical data from Phase I study of HuMax ® -TF-ADC in solid tumors
  • Oral presentation on  Phase II study of daratumumab in double refractory multiple myeloma
  • Additional data on daratumumab, Arzerra ® (ofatumumab) and HuMax-AXL-ADC to be presented
  • Abstracts available online at ASCO website

Copenhagen, Denmark; May 13, 2015 – Genmab A/S (OMX: GEN) announced today that data on HuMax-TF-ADC, daratumumab, ofatumumab and HuMax-AXL-ADC will be presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, May 29 – June 2.  Key presentations will include the first preliminary clinical data from the Phase I study of HuMax-TF-ADC in solid tumors and comprehensive data from the Phase II study of daratumumab in double refractory multiple myeloma.  With the exception of the Phase II daratumumab data, which has been designated as a late breaking abstract by ASCO, the abstracts have been published at the ASCO website at http://abstracts.asco.org.

HuMax-TF-ADC Phase I Data Preliminary safety and efficacy data from a Phase I dose escalation study of HuMax-TF-ADC to treat multiple solid tumors will be presented in a poster presentation at the ASCO meeting.  Data for 18 patients is included in the abstract for this ongoing study.  Preliminary data show a manageable safety profile with no dose limiting toxicities at doses of HuMax-TF-ADC of up to 1.8 mg/kg and preliminary evidence of anti-tumor efficacy was observed, including prolonged disease stabilization in an ovarian cancer patient (23 weeks), two castration resistant prostate cancer (CRPC) patients (18 and 36 weeks) and a confirmed partial response (PR) in a patient with cervical cancer.  Data from further patients will be included in the poster at the time of the presentation including observed dose limiting toxicities in the 2.2 mg/kg cohort. Part 2 of the study will now be expanded from 30 to 80 patients, bringing the total patients in this study to approximately 110 patients.

Abstract details: A phase I, first-in-human study to evaluate the tolerability, pharmacokinetics and preliminary efficacy of HuMax-tissue factor-ADC (TF-ADC) in patients with solid tumors – Abstract #2570, Poster session, Sunday, May 31, 8:00AM to 11:30AM CDT

List of Further Abstracts to Be Presented

Daratumumab Phase 2 study of daratumumab (DARA) monotherapy in patients with ≥3 lines of prior therapy or double refractory multiple myeloma (MM): 54767414MMY2002 (Sirius) – Late breaking abstract #LBA8512, Oral Presentation, Tuesday, June 2, 11:21AM to 11:33AM CDT This abstract has been designated a late breaking abstract and the embargo will be lifted on Saturday May 30 at 6:30AM CDT. The abstract will be included in a press briefing by ASCO on Saturday, May 30 from 8:00AM to 9:00AM CDT.

Twin randomized studies of daratumumab (DARA; D) plus standard of care (lenalidomide/dexamethasone or bortezomib/dexamethasone [DRd or DVd]) versus Rd or Vd alone in relapsed or refractory multiple myeloma (MM): 54767414MMY3003 (Pollux) and 54767414MMY3004 (Castor) - Abstract #TPS8609, Poster session, Sunday, May 31, 8:00AM to 11:30AM CDT

A randomized open-label study of bortezomib, melphalan, and prednisone (VMP) versus daratumumab (DARA) plus VMP in patients with previously untreated multiple myeloma (MM) who are ineligible for high-dose therapy: 54767414MMY3007 (Alcyone) – Abstract #TPS8608, Poster session, Sunday, May 31, 8:00AM to 11:30AM CDT

Assessing clinical response in multiple myeloma (MM) patients treated with monoclonal antibodies (mAbs): Validation of a daratumumab IFE reflex assay (DIRA) to distinguish malignant M-protein from therapeutic antibody – Abstract #8590, Poster session, Sunday, May 31, 8:00AM to 11:30AM CDT

Pre-clinical translational studies of daratumumab in patients with myeloma or AL amyloidosis undergoing autologous hematopoietic stem cell transplantation (SCT) – Abstract #8587, Poster session, Sunday, May 31, 8:00AM to 11:30AM CDT

Ofatumumab Results of a phase III randomized, controlled study sponsored by Gilead Sciences, evaluating the efficacy and safety of idelalisib (IDELA) in combination with ofatumumab (OFA) for previously treated chronic lymphocytic leukemia (CLL) – Abstract #7023, Poster Session, Sunday, May 31, 8:00AM to 11:30AM CDT

HuMax-AXL-ADC Preclinical efficacy studies using HuMax-Axl-ADC, a novel antibody-drug conjugate targeting Axl-expressing solid cancers – Abstract #3066, Poster session, Saturday, May 30, 8:00AM to 11:30AM CDT

About HuMax-TF-ADC HuMax-TF-ADC is an antibody-drug conjugate (ADC) composed of a human antibody against tissue factor (TF) conjugated to Seattle Genetics' clinically validated cytotoxic drug . HuMax-TF-ADC is being developed for the treatment of solid cancers. Based on its high expression on many solid tumors and its rapid internalization, TF is a suitable target for an ADC approach. Genmab is developing HuMax-TF-ADC using Seattle Genetics' ADC technology under an agreement between the companies. 

About daratumumab Daratumumab is a human CD38 monoclonal antibody with broad-spectrum killing activity. Daratumumab is in clinical development for multiple myeloma (MM) and non-Hodgkin’s lymphoma (NHL). Daratumumab targets the CD38 molecule which is highly expressed on the surface of multiple myeloma cells. Daratumumab may also have potential in other cancers on which CD38 is expressed, including diffuse large B-cell lymphoma, chronic lymphocytic leukemia, acute lymphoblastic leukemia, plasma cell leukemia, acute myeloid leukemia, follicular lymphoma and mantle cell lymphoma.  Daratumumab has been granted Breakthrough Therapy Designation from the US FDA.  In August 2012, Genmab granted Janssen Biotech, Inc. an exclusive worldwide license to develop and commercialize daratumumab.

About ofatumumab Arzerra (ofatumumab) is a human monoclonal antibody that is designed to target the CD20 molecule found on the surface of chronic lymphocytic leukemia (CLL) cells and normal B lymphocytes.

In the United States, Arzerra is approved for use in combination with chlorambucil for the treatment of previously untreated patients with CLL for whom fludarabine-based therapy is considered inappropriate. In the European Union, Arzerra is approved for use in combination with chlorambucil or bendamustine for the treatment of patients with CLL who have not received prior therapy and who are not eligible for fludarabine-based therapy. In more than 50 countries worldwide, Arzerra is also indicated as monotherapy for the treatment of patients with CLL who are refractory after prior treatment with fludarabine and alemtuzumab.

Arzerra is not approved anywhere in the world in combination with idelalisib for previously untreated chronic lymphocytic leukemia.

Please see full Prescribing Information, including Boxed WARNING for Arzerra (ofatumumab) .

Arzerra is marketed under a co-development and collaboration agreement between Genmab and Novartis.

About HuMax-AXL-ADC HuMax-AXL-ADC is an antibody-drug conjugate (ADC) combining a high affinity human monoclonal antibody against AXL with Seattle Genetics’ clinically validated cytotoxic drug. AXL is a signaling molecule involved in multiple processes of tumor development and progression. The target molecule is highly expressed on a variety of solid cancers.  Genmab is developing HuMax-AXL-ADC using Seattle Genetics’ ADC technology under a license agreement between the companies.

About Genmab Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated human antibody therapeutics for the treatment of cancer.  Founded in 1999, the company currently has one marketed antibody, Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications and daratumumab in clinical development for multiple myeloma and non-Hodgkin’s lymphoma, in addition to other clinical programs, and an innovative pre-clinical pipeline.  Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody® platform for generation of bispecific antibodies, and the HexaBody® platform which creates effector function enhanced antibodies. Genmab's deep antibody expertise is expected to provide a stream of future product candidates.  Partnering of selected innovative product candidates and technologies is a key focus of Genmab’s strategy and the company has alliances with top tier pharmaceutical and biotechnology companies.  For more information visit www.genmab.com .  

Contact:           Rachel Curtis Gravesen, Senior Vice President, Investor Relations & Communications T: +45 33 44 77 20; M: +45 25 12 62 60; E: r.gravesen@genmab.com

This Company Announcement contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com . Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements in relation to actual results, unless required by law.

Genmab A/S and its subsidiaries own the following trademarks: Genmab ® ; the Y-shaped Genmab logo ® ; Genmab in combination with the Y-shaped Genmab logo™; the DuoBody logo ® ; the HexaBody logo™; HuMax ® ; HuMax-CD20 ® ; DuoBody ® ; HexaBody ® and UniBody ® . Arzerra ® is a trademark of Novartis Pharma AG.

Company Announcement no. 21 CVR no. 2102 3884

Genmab A/S Bredgade 34E 1260 Copenhagen K Denmark

Scroll down for more posts ▼

Top 10 Most Recent News Articles

CICYBELL's Black Friday Is a Fashionist's Dream

Updated Category News Views 111

Stepping Into the Fashion Frenzy It’s that time of year again, where shoppers are girding up for Black Friday. And here comes CICYBELL, ready to dish up some meaty discounts that would turn even the most hardened cynic into a frenzied shopper. Alright, maybe that’s a touch dramatic, but let’s break down what this fashion brand is cooking up in their latest sale....

Continue Reading
HLTH USA 2026 Spotlights AI and Health Innovation

Updated Category News Views 30

The Pulse of Innovation at HLTH USA 2026 Diving headfirst into the heart of healthcare innovation, HLTH USA 2026 kicked off with gusto in Las Vegas. Discussions are swirling around AI advancements and the next generation of payer-provider collaboration. Who knew healthcare could be this thrilling? The event is already shaping up to be a powerhouse of change, buzzing with...

Continue Reading
ELEGRP Makes Dyson Supersonic Global Voltage Ready

Updated Category News Views 36

Plugging Into the Future of Travel ELEGRP's latest move brings the Dyson Supersonic Travel hair dryer into the limelight, all decked out with global voltage compatibility. It's like the Swiss Army knife of hair dryers—one minute it’s working on 100V, next it’s flipping over to a juicy 240V, without breaking a sweat. The ALCI Difference: Safety Takes Center Stage...

Continue Reading
Veritran's Bold Move: Acquiring PrismaCampaigns Inc.

Updated Category News Views 0

Veritran's Strategic Leap Forward They're not messing around, folks. Veritran just made a power move by acquiring 100% of PrismaCampaigns Inc., and it’s more than just another day in the office. This marks a pivotal expansion of their American footprint, and they're zeroing in on our banks and credit unions with laser precision. Why This Matters for Financial...

Continue Reading
Guangdong's APEC Trade: Deep Ties, Big Stakes

Updated Category News Views 259

A New Chapter in Guangdong's Economic Story Swing by the bustling streets of Shenzhen, and you'll catch more than a whiff of change in the air. With China gearing up to host the APEC Economic Leaders' Meeting for the third time, Guangdong is under the magnifying glass. But it's not just the international attention landing on the province that’s worth the chatter —...

Continue Reading
Bloomberg, HKEX Expand Offshore RMB Bond Indices

Updated Category News Views 176

A Move to Elevate Dim Sum Bonds If you're wondering what's cooking in the bond market arena, Bloomberg and HKEX just turned up the heat with a new family of RMB bond indices. These aren't just any run-of-the-mill indices; they're targeting the offshore RMB market, affectionately called the Dim Sum bond market. For those of us grizzled vets in the trading world, this is...

Continue Reading
Avoid FOGs: Illinois Water's Holiday PSA

Updated Category News Views 0

Don't Ignore the Kitchen Sink This Holiday You ever poured something down the drain and just prayed it wouldn't come back to bite you later? Well, Illinois American Water is throwing up a big, red flag about doing exactly that during the holidays. When we're all busy passing the gravy boat and diving into festive feasts, it's easy to forget the after-party might just turn...

Continue Reading
Pollo AI Unveils York AI: Automating Social Growth

Updated Category News Views 151

York AI Debuts as the New Kid on the Block Amid the hustle and bustle of a tech-savvy Singapore, Pollo AI’s latest offering, York AI, sashays onto the scene with the promise of putting social media growth on cruise control. We're talking about a digital sidekick that seems to know your online persona better than you do. It’s tailored for everyone from the small-time...

Continue Reading
Parallels Desktop Tops 2026 Picks for Windows on Mac

Updated Category News Views 41

Diving into the Cross-Platform Conundrum Now, I've been in the trenches long enough to know that when companies start relying on Mac computers but can't ditch their essential Windows apps, they're bound to hit a digital brick wall. Picture this—accounting, enterprise management, all that jazz that still needs Windows to function. For those jumping between these two...

Continue Reading
Dr. Obeng Joins WellcomeMD with Special Offer for Patients

Updated Category News Views 23

New Beginnings in Concierge Medicine In late October, WellcomeMD opened its doors to Dr. Paa-Kofi Obeng—an arrival greeted with considerable anticipation in Richmond's medical scene. This isn't just any run-of-the-mill staff addition; Dr. Obeng brings with him over a decade of experience from places like the Veterans Administration Medical Center. He's armed with a...

Continue Reading

Top 5 Most Recently Viewed Articles

Ripplecoin Mining Unveils Revolutionary Cloud Mining App

Updated Category News Views 160

Introducing the Latest in Cloud Mining Technology Ripplecoin Mining has launched a state-of-the-art mobile application designed to enhance the cloud mining experience for cryptocurrency enthusiasts. Since its inception in 2017, Ripplecoin Mining has positioned itself as a leader in the industry. This exciting update allows users to effortlessly manage their cryptocurrency...

Continue Reading
AMSURG Centers Shine in National Human Experience Awards 2025

Updated Category News Views 108

AMSURG Centers Celebrate National Recognition AMSURG, a distinguished leader in ambulatory surgery center services, is thrilled to announce that three of its esteemed centers have been honored in the latest round of the Human Experience Awards. These awards, conferred by a renowned leader in healthcare experience solutions, aim to recognize organizations across the...

Continue Reading
Wynn Resorts Gains Momentum with Upgraded Growth Outlook

Updated Category News Views 276

Wynn Resorts got a jolt back in 2024 when Morgan Stanley raised its rating from Equal-weight to Overweight, pushing the price target up from $97 to $104. Traders perked up at the mention of a 25% upside, which suggested to many that there was solid potential brewing for those willing to take the plunge. Factors Driving the Upgrade: Opportunity Awaits This upgrade wasn't...

Continue Reading
Innovative Toilet Cleaning Solution for a Fresher Home

Updated Category News Views 117

Introducing the Sani Flush – A Revolution in Toilet Cleaning In the quest for cleaner and more sanitary bathroom experiences, a new invention has emerged. The Sani Flush - Toilet Refresher is designed to transform the way we think about toilet hygiene. Developed by a passionate inventor, this product offers a unique solution for maintaining cleanliness in toilet bowls...

Continue Reading
Understanding the Legal Rights of Fly-E Group Stakeholders

Updated Category News Views 205

Overview of Fly-E Group, Inc. Fly-E Group, Inc. is committed to revolutionizing sustainable transportation through its innovative electric vehicles powered by cutting-edge lithium battery technology. Investors in the company should stay informed about potential legal matters that may affect their investments, especially in light of recent events. Class Action Securities...

Continue Reading